Lakeshore Biopharma Co. Ltd. logo

Lakeshore Biopharma Co. Ltd. (LSB)

Delisted
NASDAQ (CM) NASDAQ (CM)
Want to track LSB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LSB is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

Lakeshore Biopharma Co. Ltd. Profile

Biotechnology Industry
Healthcare Sector
Wang Xu CEO
NASDAQ (CM) Exchange
KYG9845F1090 ISIN
CN Country
758 Employees
- Last Dividend
4 Oct 2024 Last Split
16 Mar 2023 IPO Date

Overview

LakeShore Biopharma Co., Ltd is a forward-looking biopharmaceutical entity committed to the research, development, production, and sale of vaccines and therapeutic biologics targeting infectious diseases and cancer. Born from its predecessor, YS Biopharma Co., Ltd., LakeShore Biopharma transitioned its name in May 2024, a move reflecting its evolution and expanded vision. Established in 2002 and headquartered in Beijing, China, the company exercises a global footprint through its operations in China, the United States, Singapore, the United Arab Emirates, and the Philippines. At its core, LakeShore Biopharma is pioneering through its proprietary PIKA immunomodulating technology platform, a testament to its innovative direction in the biopharmaceutical industry.

Products and Services

  • PIKA Rabies Vaccine
  • A groundbreaking vaccine leveraging the PIKA technology platform, this product represents a significant advancement in the prevention of rabies, a critical public health issue worldwide. The PIKA rabies vaccine is designed to offer enhanced immunogenicity and safety, targeting a wide demographic with its innovative approach to rabies vaccination.

  • PIKA Recombinant COVID-19 Vaccine
  • In response to the global pandemic, LakeShore Biopharma developed the PIKA recombinant COVID-19 vaccine, utilizing its novel PIKA platform to provide a potentially more efficacious and safer alternative to existing COVID-19 vaccines. This product underscores the company's agility and commitment to addressing emergent global health crises through cutting-edge biotechnological advancements.

  • PIKA YS-ON-001
  • Expanding its portfolio into the realm of cancer therapy, LakeShore Biopharma's PIKA YS-ON-001 is a testament to the company's innovative application of its PIKA platform beyond infectious diseases. This therapeutic biologic is aimed at harnessing the body's immune response to target and combat various forms of cancer, illustrating LakeShore Biopharma's ambitious endeavor into oncology.

Contact Information

Address: Building No. 2
Phone: 86 10 8920 2086